Summary In this study, we used immunohistochemical and biochemical analysis to show that gp200-MR6, a 200 kDa molecule that is functionally associated with the human interleukin 4 (IL-4) receptor complex, is expressed at high levels on normal breast epithelial tissues, at lower levels on in situ carcinomas, and that the expression is lost in the invasive carcinoma of the breast. Furthermore, a preliminary study showed that benign epithelial hyperplasia of the breast expresses the gp200-MR6 heterogeneously. Two populations of cells have been observed: MR6 positive and MR6 negative. Interestingly, MR6-positive cells were observed to have different morphology from those that were MR6 negative; the nuclei of the former were larger and rounded in shape, whereas the nuclei of the latter were relatively small and oval in shape. In sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting, monoclonal antibody MR6 detects the same molecular weight molecule in both normal and transformed tissue, indicating that the molecule is not a product of a truncated gene. The intensity of the gp200-MR6 bands correlates with the immunohistochemical data, indicating that the molecule is expressed at high levels in normal tissue and at lower levels in malignant tissue. These results suggest that analysis of gp200-MR6 expression may be useful in tumour grading and prognostic evaluation in breast cancer. Moreover, the molecule may be involved early in the process of tumorigenesis of the breast, in which a loss or a down-regulation of gp200-MR6 could contribute towards tumour development and progression via an effect on cell growth and differentiation.
In a study designed to investigate the role of the human thymic microenvironment in T-cell maturation (De Maagd et al., 1985) , the monoclonal antibody (MAb) MR6 was raised against human thymic stromal cells. MAb MR6 shows strong labelling of the cortical epithelium and much weaker labelling of macrophages, lymphocytes and dendritic cells in frozen tissue sections of human thymus (Larche et al., 1987) . Immunoelectron microscopy using gold-coupled reagents showed that the molecule detected by MAb MR6 is localised on the surface of these cells (von Gaudecker et al., 1996) .
Biochemical analysis by immunoprecipitation and Western blotting using lysates of normal thymus, B-and T-cell lines and carcinoma tissue yielded a single band of 200 kDa both under reducing and non-reducing conditions (gp200-MR6; Mat et al., 1990) . In vitro studies have shown that ligation of gp200-MR6 with MAb MR6 inhibits interleukin 4 (IL-4)-dependent immunoglobulin class switching to IgE in allergenstimulated B cells; IL-4 induced proliferation of cloned T cells and expansion of the IL-4-dependent Th2 T helper lymphocyte subset (Larche et al., 1988; Imami et al., 1994) . However, MAb MR6 does not interfere with the binding of IL-4 to the CD124 ligand-binding chain of the IL-4 receptor (IL-4R) (Imami et al., manuscript in preparation) . These data therefore indicate that gp200-MR6 is functionally associated with the IL-4R.
In a preliminary study, investigating the gp200-MR6 expression on non-thymic epithelium, we showed that all of the 20 tumours analysed, including lung, ovary, colon, bladder and thyroid, expressed the antigen (Al-Jabaari et al., 1989) . However, further studies revealed that, although all bladder tumours express the gp200-MR6 molecule, only approximately 30% of tumours of the breast and lung are MR6 positive (Mat et al., 1990; Tungekar et al., 1991 Tungekar et al., , 1996 . These data raise the possibility that changes in gp200-MR6 expression may be related to tumour development. In this study, in order to investigate further the connection between the gp200-MR6 and tumorigenesis, we have focused on tumours of the breast.
The normal resting human mammary gland consists of a branching system of ducts terminating as groups of smaller ductules (acini). Their walls are formed by an inner layer of lining epithelium (luminal epithelium) and by an outer layer of myoepithelium (Figure 1) (Taylor-Papadimitriou and Lane, 1987; Guelstein et al., 1988; Rudland and Hughes, 1989) . Myoepithelial cells can be specifically stained with antibodies to smooth muscle actin (Bussolati et al., 1980) and to CDIO [anti-common acute lymphoblastic leukaemia antigen (anti-CALLA)] (Mahendran et al., 1989) .
We used these markers for luminal and myoepithelial cells together with MAb MR6 to analyse the distribution of gp200-MR6 in normal and hyperplastic tissue samples and a panel of other markers to study the expression of gp200-MR6 in the hyperplasia cases. Our data indicate that gp200-MR6 is homogeneously expressed on both luminal and myoepithelial cells in the normal mammary duct, heterogeneously expressed in benign hyperplasia, and is down-regulated in invasive carcinomas of the breast. (Burchell et al., 1983 (+ +) for moderate and (+ + +) for strong staining. Anticytokeratin staining was scored as + + + since the intensity of staining was very strong in all samples studied. The staining intensity of the MAb MR6 was scored relative to that obtained with the anti-cytokeratin antibody and with the negative control. MAb MR6 was able to detect the gp200-MR6 on the ducts in all the normal breast tissue samples studied. The staining intensity was scored as + + in 86% of the normal samples, whereas in 7% of the normal samples the staining intensity was weaker (score + ), and in another 7% the staining was very strong (score + + +) (Figure 2 ). The staining was homogeneous on luminal epithelium (Figure 3a , small arrowhead) and myoepithelium ( Figure 3a, (Figure 3d) . In all the eight cases of benign hyperplasia of the breast studied, unusual heterogeneous expression of gp200-MR6 was observed (Figure 3e ). This pattern was seen only in the hyperplastic inner layer of the duct (luminal epithelium) where some cells were MR6-positive and others were MR6 MR6-negative. These cells were not stained with antibodies to CDIO and to sm-actin, but they were strongly and homogeneously stained with LP34 ( Figure 3f ) and HMFG-1 (indicating that they were luminal epithelial cells). The outer layer (myoepithelium, CDIO positive, sm-actin positive) was homogeneously MR6-positive (Figure 4, large arrowhead) . The MR6-positive luminal epithelial cells were bound together in a clumpy form and appeared to be linked to the basal layer (Figure 4, small arrowheads) .
Materials and methods
Consecutive sections of each tissue were stained with other antibodies, such as LP34 (Figure 3f) (Gerdes et al., 1984) , stained the majority of the MR6-positive cells, and also some of the MR6-negative cells. Furthermore, some morphological differences were observed between the MR6-positive and the MR6-negative cells. Gp-200-MR6 expression in breast tumours AA Al-Tubuly et al 1009 The nuclei of MR6-positive cells were larger and rounder, whereas the nuclei of MR6-negative cells were relatively smaller and oval in shape (Figure 4 ).
SDS-PAGE and Western blotting
Lysates from normal breast tissue, benign hyperplasia, in situ carcinoma, or from invasive malignant tissues were run on SDS-PAGE, followed by transfer to a nylon membrane for Western blotting. The MAb MR6 detected a molecule of approximately 200 kDa (sometimes 210 kDa) in all the different lysates. The same 200 kDa band was detected in a lysate from a normal human thymus, which was used as a positive control (Figure 5 ). The intensity of the bands detected gave an indication of the amount of gp200-MR6 present in each sample. The normal thymic lysate (HT) contained the largest quantity of the gp200-MR6 molecule and invasive carcinoma (IC) of the breast contained the least. Other samples showed intermediate levels of gp200-MR6, with normal (NB) expressing levels greater than hyperplasia (BH), which in turn were greater than carcinoma in situ (IS). This observation is in agreement with the immunohistochemical data.
Discussion
Previous studies on the expression of the IL-4R-associated gp200-MR6 molecule have indicated that, while all bladder tumours express the gp200-MR6 molecule, only approximately 30% of tumours of the breast, lung and colorectal tumours are MR6-positive (Al-Jabaari et al., 1989; Mat et al., 1990; Tungekar et al., 1991 Tungekar et al., ,1996 . In this -paper we present a more detailed analysis of both benign and malignant tumours of the breast. Our data reveal that gp200-MR6 expression is associated with benign and most in situ tumours, while it is lost from the majority of invasive carcinomas, thus raising the possibility that loss of gp200-MR6 may play a role in tumorigenesis. Interestingly, we also observed heterogeneity of expression of gp200-MR6 within individual samples of benign hyperplasia; this correlates with morphological heterogeneity and may have implications for disease progression.
In breast cancer, gene amplification and/or overexpression of certain antigens (such as c-erbB-2, also known as HER-2), have been associated with metastasis and poor prognosis (Slamon et al., 1987) . The c-erbB-2 oncogene becomes pathologically activated by a truncation of its extracellular ligand-binding domain leading to continuous triggering of cell division (Downward et al., 1984) . Abnormal expression of such molecules can be due to either amplification or structural alteration of the normal cellular proto-oncogene encoding the receptor protein, resulting in either an increase in the number of receptor molecules per cell or in a structural variant of the receptor (Ullrich et al., 1984) . However, Bands were visualised by using ECL method. (Steeg et al., 1988; Bevilacqua et al., 1989) . We have analysed the distribution of the gp200-MR6 in normal and transformed breast tissue in terms of intensity of expression and its distribution in different types of breast tissues. In normal breast tissues, gp200-MR6 is expressed on both luminal epithelium and myoepithelium (moderate in 86% of cases, strong in 7% of cases). In benign hyperplastic tissues, the expression of gp200-MR6 was heterogeneously distributed, with moderate staining (+ +) in some cells and no staining (-) (Tepper et al., 1989) and an antitumour effect in vivo in the nude mouse xenograft model (Lahm et al., 1994) . The role, if any, of gp200-MR6 in such tumour suppression is currently under investigation. However, our observation that in hyperplasia of the breast the gp200-MR6 molecule is lost while IL-4R continues to be expressed is consistent with its proposed tumour-suppression function.
The immunolabelling of the epithelial hyperplasia samples showed an interesting differential labelling pattern with MR6-positive and MR6-negative cell population within a single tissue. The strange pattern of MR6-positive cells, which was arranged in grape-like clumps (Figure 4) , raised the question of whether these cells (MR6-positive) originated from the myoepithelial layer. However, antibodies that are used routinely to delineate myoepithelium (anti-smooth muscle actin, CALLA) did not stain these MR6-positive clumps, instead they defined clearly the myoepithelial and basement membrane layers, indicating that the stained hyperplastic cells in the lumen were not myoepithelial. Furthermore, HMFG-1 gave a strong and homogeneous staining of the cells in question confirming that they were luminal. Carcinoma in situ, a proliferation of presumably malignant cells, confined to the mammary ducts with no evidence of invasion through the basement membrane into the surrounding stroma, is sometimes mistaken for atypical hyperplasia, which is a nonmalignant proliferation of epithelial cells. The histological differentiation of pure ductal carcinoma in situ (DCIS) from atypical ductal hyperplasia (ADH) is usually difficult, and some cases may create diagnostic disagreement among histopathologists. It has been found that ADH has a significant role as a marker for high risk of breast cancer development. Moderate or severe benign hyperplasia, where cells show a mild variation of cytological pattern with both oval and round nuclei, were found to have a slight elevation of breast cancer risk (Page et al., 1985; Tavassoli and Norris, 1990) , and in a recent study it has been found that 17% of DCIS cases were associated with ADH (Lennington et al., 1994) . In this study we have analysed eight cases of moderate hyperplasia (five to ten epithelial layers), and two of them were associated with DCIS components. The heterogeneity in gp200-MR6 expression that we have observed in hyperplasia, and the variation in cell morphology, may be helpful as a prognostic measure, where the increased variation in gp200-MR6 expression and in cytological pattern may indicate an increased risk of malignant transformation.
In conclusion, we have shown that, while gp200-MR6 is expressed on normal epithelial cells, benign tissue and in situ tumours, it is lost from the invasive carcinomas of the breast.
Moreover, its expression within individual hyperplastic samples is heterogeneous. Analysis of this molecule may therefore be useful in tumour grading and prognostic evaluation. Further, functional studies are required to test the hypothesis that gp200-MR6 has tumour-suppressive function and that its loss is a primary cause of tumorigenesis.
